Rx Drug Promotion Studies Target Biosimilar Disclosures, Unapproved Uses, Multiple Indications

US FDA proposes studies to look at the impact of disclosure of a product’s secondary claims and biosimilar designation; disclosure about unapproved uses; and the impact of citing a drug’s multiple indications in TV ads.

Conceptual business illustration with the words direct-to-consumer advertising — FDA proposes three new studies of Rx drug promotion • Source: Shutterstock

The US Food and Drug Administration plans to conduct a trio of new studies to assess how prescription drug promotions impact the perceptions of healthcare professionals and consumers.

In one study, the Office of Prescription Drug Promotion plans to evaluate disclosures about a product's secondary clinical benefit and...